Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 24:12:667-673.
doi: 10.2147/IJWH.S260073. eCollection 2020.

Comparison of Low Dose versus High Dose of Oxytocin for Initiating Uterine Contraction During Cesarean Delivery: A Randomized, Controlled, Non-Inferiority Trial

Monsicha Somjit  1 , Jaruta Surojananon  1 , Kiattisak Kongwattanakul  2 , Cattleya Kasemsiri  1 , Monthira Sirisom  1 , Khuantipa Prawannoa  1 , Kaewjai Thepsuthammarat  3 , Ratana Komwilaisak  2
Affiliations

Comparison of Low Dose versus High Dose of Oxytocin for Initiating Uterine Contraction During Cesarean Delivery: A Randomized, Controlled, Non-Inferiority Trial

Monsicha Somjit et al. Int J Womens Health. .

Abstract

Background: Oxytocin is used for initiating uterine contraction and preventing postpartum hemorrhage during caesarean delivery. Using a lower dosage of oxytocin may lower the risk of adverse effects while still being effective in stimulating initial uterine contraction. We aimed to compare the effectiveness and side effects of the standard 10 IU bolus of oxytocin with those of a 5 IU bolus during caesarean delivery.

Patients and methods: We enrolled women in a randomized, double-blind, study comparing intravenous injections of high-dose (10 IU) and low-dose (5 IU) oxytocin administered after clamping of the umbilical cord. The primary outcome was adequate uterine contraction within the first 3 mins after administration. Secondary outcomes included uterine tone, use of additional uterotonic agents, additional obstetrics procedures, and oxytocin-related adverse events.

Results: A total of 155 women underwent randomization, with 78 in the low-dose group and 77 in the high-dose group. The proportion of women with adequate uterine contraction during the first 3 mins was 84.6% in the low-dose group and 77.9% in the high-dose group (relative risk, 1.09; 95% CI, 0.93 to 1.26). Methylergonovine maleate was used in 14.1% of cases in the low-dose group and 36.4% in the high-dose group (relative risk, 0.40; 95% CI, 0.22 to 0.73). The necessity for additional obstetric procedures, estimated blood loss >500 mL, neonatal outcomes, and oxytocin-related adverse effects did not differ significantly between the two groups.

Conclusion: The 5 IU bolus of oxytocin was noninferior to the standard 10 IU bolus of oxytocin for initiating adequate uterine contraction, required fewer additional uterotonic agents, and led to fewer oxytocin-related adverse events.

Keywords: cesarean section; oxytocin; uterine contraction.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to report for this work.

Figures

Figure 1
Figure 1
Consort flowchart of the study.
See this image and copyright information in PMC

References

    1. The International Federation of Gynecology and Obstetrics. PPH leading to unnecessary deaths. 2018; Available from: https://www.figo.org/news/pph-leading-unnecessary-deaths-0016005.
    1. Nathan LM. An overview of obstetric hemorrhage. Semin Perinatol. 2019;43(1):2–4. doi: 10.1053/j.semperi.2018.11.001 - DOI - PubMed
    1. Grobman WA, Bailit JL, Rice MM, et al. Frequency of and factors associated with severe maternal morbidity. Obstet Gynecol. 2014;123(4):804–810. doi: 10.1097/AOG.0000000000000173 - DOI - PMC - PubMed
    1. Callaghan WM, Mackay AP, Berg CJ. Identification of severe maternal morbidity during delivery hospitalizations, United States, 1991–2003. Am J Obstet Gynecol. 2008;199(2):133.e1–8. doi: 10.1016/j.ajog.2007.12.020 - DOI - PubMed
    1. Creanga AA, Berg CJ, Ko JY, et al. Maternal mortality and morbidity in the United States: where are we now? Journal of Women’s Health. 2014;23(1):3–9. doi: 10.1089/jwh.2013.4617 - DOI - PMC - PubMed

LinkOut - more resources